Escient Pharmaceuticals

Also Clin1 uremic pruritus, Clin0 undisclosed; EP262 Clin1 chronic spontaneous urticaria, Clin1 chronic inducible urticaria, Clin0 atopic dermatitis, Clin0 undisclosed; 2 programs RD undisclosed

Escient Pharmaceuticals is developing therapeutics that target G-protein coupled receptors (GPCRs) to treat neurosensory inflammatory disorders. GPCRs are cell surface receptors that make good drug targets being both accessible and causal to many disease pathways. Using state-of-the-art medicinal chemistry and biological tools, Escient is identifying oral therapeutics that can target Mas-related GPCRs (MRGPRs), a class of chemosensory GPCRs expressed on sensory neurons and immune cells that are at the initiation of the neuro-inflammatory disease cascade. Escient’s lead programs targeting MRGPRs, EP262 and EP547, are currently being evaluated for chronic urticaria (hives) and cholestatic pruritus (chronic itchy skin).

Jobs: